Hopp til hovedinnhold

Urinsyregikt og kosthold

Kostholdet har stor betydning ved urinsyregikt. Urinsyre dannes ved nedbrytning av puriner. Noe dannes i kroppen, men en tredjedel kommer fra maten vi spiser.

Sist revidert:


Målsetting

Kost- og livsstilsråd ved urinsyregikt

Kosthold og livsstilsanbefalinger

Oppfølging

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Urinsyregikt. Referanselisten for dette dokumentet vises nedenfor.

  1. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the management of gout. Rheumatology 2017; 56: e1–e20. doi.org 
  2. Uhlig T, Halsan Liff M, Brække Norheim K, et al. Urinsyregikt (Arthritis urica). Veileder om urinsyregikt, Norsk Revmatologisk Forening, 2022.
  3. Clebak KT, Morrison A Croad JR. Gout: Rapid Evidence Review. Am Fam Physician 2020 Nov 1;102(9):533-538. PubMed 
  4. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–2052.
  5. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23(2):192–202. PMID: 21285714. PubMed 
  6. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–667. PMID: 24431399. PubMed 
  7. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensible healthy, vigorously active men. Am J Clin Nutr 2008; 87: 1480-7. pmid: 18469274 PubMed 
  8. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309-12. pmid: 18244959 PubMed 
  9. Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA 2010; 304: 2270-8. pmid: 21068145 PubMed 
  10. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-8. PubMed 
  11. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 2019 PMID: 31167758 PubMed 
  12. Janssens HJ, Fransen J, van de Lisdonk EH, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010; 170: 1120-6. pmid:20625017 PubMed 
  13. Uhlig T, Eskild T, Hammer HB. Urinsyregikt – nytt innen diagnostikk og behandling. Tidsskr Nor Lægeforen 2016; 136: 1804-7. doi:10.4045/tidsskr.16.0147 DOI 
  14. Dalbeth N, Kalluru R, Aati O, et al. Tendon involvment in the feet of patients with gout: a dual-energy CT study. Ann Rheum Dis 2013; 72: 1545-8. pmid: 23334212 PubMed 
  15. Gaffo AL. Clinical manifestations and diagnosis of gout. UpToDate, last updated Dec 01, 2021. UpToDate 
  16. Qaseem A, McLean RM, Starkey M, et al. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):52–57. PMID: 27802479.
  17. Bongartz T, Glazebrook KN, Kavros SJ, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 2014. pmid: 24671771 PubMed 
  18. Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592-600. PubMed 
  19. van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120. pmid:25225849 PubMed 
  20. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2019. PMID: 31666237 PubMed 
  21. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013. pmid: 23868909 PubMed 
  22. Vinik O, Wechalekar MD, Falzon L, et al. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. J Rheumatol Suppl. 2014;92:70-4. pmid: 23024028 PubMed 
  23. Juraschek SP, Gelber AC, Choi HK. Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid. Arthritis Rheumatol 2016; 68: 3002-9. pmid:27523583 PubMed 
  24. Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-1446. PubMed 
  25. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016. PMID: 27457514 PubMed 
  26. Neoqi T, Chen C, Niu J et al. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med, published online 21 January 2014. pmid: 24440541 PubMed 
  27. Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. Epub 2015 Jun 24. pmid: 26099603 PubMed 
  28. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068. PMID: 20131255. PubMed 
  29. Billy CA;Lim RT;Ruospo M;Palmer SC;Strippoli GFM. Corticosteroid or Nonsteroidal Antiinflammatory Drugs for the Treatment of Acute Gout: A Systematic Review of Randomized Controlled Trials. J Rheumatol. 2017 Aug 1. pii: jrheum.170137. (Review) PMID: 28765243 PubMed 
  30. Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: A pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016. pmid: 26903390 PubMed 
  31. Janssens HJEM, Janssen M, van de Lisdonk EH et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854-60. PubMed 
  32. Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014 Jan 29. pmid: 24472084 PubMed 
  33. Dalbeth N, Merriman TR, Stamp LK.Gout.Lancet. 2016 Oct 22;388(10055):2039-2052. Epub 2016 Apr 21.PMID:27112094. PubMed 
  34. Liew JW, Gardner GC. Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis. J Rheumatol 2019; 46: 1345-9. pmid:30647192 PubMed 
  35. Taylor TH, Mecchella JN, Larson RJ et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125: 1126-34. pmid:23098865 PubMed 
  36. Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2016. pmid:27658678 PubMed 
  37. Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;10. pmid: 25314636 PubMed 
  38. Stamp LK, Taylor WJ, Jones PB et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529-36. PubMed 
  39. Feig DI, Soletsky B, Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA 2008; 300: 924-32. PubMed 
  40. MacKenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020. pmid:33181081 PubMed 
  41. Lim SY, Lu N, Choi HK. Septic arthritis in gout patients: a population-based cohort study. Rheumatology (Oxford) 2015; 54: 2095-9. PMID: 26170377 PubMed 
  42. O'Dell JR, Brophy MT, Pillinger MH, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. N Engl J Med 2022. doi:10.1056/EVIDoa2100028 DOI 
  43. Voelker R. Another Warning for Febuxostat. JAMA. 2019;321(13):1245. doi:10.1001/jama.2019.3043 DOI 
  44. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018;378(13):1200-10. New England Journal of Medicine 
  45. Hong J-Y, Lan T-Y, Tang G-J, et al. Gout and the risk of dementia. Arthritis Res Ther 2015;17: 139. PMID: 26018424. PubMed 
  46. Shahin L, Patel KM, Heydari MK, Kesselman MM. Hyperuricemia and Cardiovascular Risk. Cureus. 2021;13(5):e14855. Published 2021 May 5. PMID: 34104597 PubMed 
  47. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900. PubMed 
  48. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; for the MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-10. PubMed 
  49. Huang W-S, Lin C-L, Tsai C-H, Chang K-H. Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. J Inestig Med 2020; 68: 972-9. pmid:32098832 PubMed 
  50. Chen J-H, Lan J-L, Cheng C-F, et al. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study. J Rheumatol 2015; 42: 1694-1701. pmid: 26077411 PubMed 
  51. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013; 347: f4262. pmid: 23869090 PubMed 
  52. Sultan AA, Muller S, Whittle R et al. Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy. CMAJ 2019; 191: E597-E603. pmid:31160496 PubMed 
  53. Singh JA, Uhlig T. Chasing crystals out of the body: will treat to serum urate target for gout help us get there?. Ann Rheum Dis 2017; 76: 629-31. pmid:28031165 PubMed 
  54. Ogdie A, Taylor WJ, Neogi T et al. Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis Rheumatol 2017; 69(2): 429-38. pmid:27748084 PubMed 
  55. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system?. Ann Rheum Dis 2014; 73: 1598-600. pmid:24718961 PubMed